A randomized non-inferiority study published in Lancet Healthy Longevity examined whether stopping statins at age 75 in people without a history of cardiovascular disease increased deaths. The trial found that, in this relatively healthy French population, discontinuing statin therapy did not lead to an increase in mortality compared with continuing treatment. The authors emphasize that the results do not establish stopping as superior to remaining on therapy; rather, they indicate that stopping may not make patients worse off in the specific population studied.
The article reports that the research was conducted in France and involved older adults aged 75 at the point of consideration for discontinuing therapy. Participants were described as having no prior cardiovascular disease and generally being healthier than many older populations, which the investigators note as an important characteristic of the study cohort. The report describes the study as a randomized non-inferiority trial, but the STAT News summary does not provide specific numerical details such as sample size, follow-up duration, absolute rates of outcomes, or statistical margins used. Those specifics were reported in the Lancet Healthy Longevity paper itself, which the STAT News piece references.
The authors of the trial and the STAT News coverage both caution that the findings may not translate to other settings or to people at higher cardiovascular risk. They point to several limitations and reasons for caution:
The coverage also highlights a broader evidence gap: historically, older adults have been underrepresented in prevention trials, and the relationship between cholesterol levels and cardiovascular events appears to weaken with advancing age according to prior research cited by the article.
The study does not prompt a blanket recommendation to stop statins at age 75. Instead, the authors and STAT News emphasize shared decision-making:
The investigators explicitly call for additional research: replication with longer follow-up and evaluation in populations with greater cardiovascular risk or lower baseline health status. They note the current study fills a gap but is not definitive. The STAT News summary reports the authors’ position that the study raises the question of whether some older adults could safely reduce medication burden, but stresses that clinical implementation should await further data and individualized assessment.
The trial appears at a moment when cholesterol prevention guidance has been evolving; STAT News notes recent guideline changes that expanded consideration of statin therapy to much younger adults. That shift underscores a tension in practice: while some guidelines advocate earlier and broader primary prevention, this trial explores whether selective deprescribing may be appropriate for older, low-risk adults. The article frames the findings as a prompt for clinicians and patients to weigh preventive intensity across the life course rather than as a directive to discontinue statins uniformly at a certain age.
In a healthy, low-risk French population aged 75, stopping statins did not increase deaths during the study period reported. The evidence is specific to the study population and follow-up, and the authors recommend further trials with longer durations and in higher-risk groups. Clinicians should not universally stop statins at age 75 on the basis of this study alone; instead, use shared decision-making that incorporates patient values, comorbidity, cardiovascular risk, and the acknowledged limitations of the current evidence.